Akero Therapeutics Inc (AKRO)
32.04
-0.30
(-0.91%)
USD |
NASDAQ |
Nov 04, 16:00
32.04
0.00 (0.00%)
After-Hours: 20:00
Akero Therapeutics Enterprise Value: 1.499B for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 1.499B |
| November 01, 2024 | 1.519B |
| October 31, 2024 | 1.415B |
| October 30, 2024 | 1.406B |
| October 29, 2024 | 1.478B |
| October 28, 2024 | 1.338B |
| October 25, 2024 | 1.311B |
| October 24, 2024 | 1.271B |
| October 23, 2024 | 1.265B |
| October 22, 2024 | 1.329B |
| October 21, 2024 | 1.420B |
| October 18, 2024 | 1.443B |
| October 17, 2024 | 1.415B |
| October 16, 2024 | 1.431B |
| October 15, 2024 | 1.353B |
| October 14, 2024 | 1.358B |
| October 11, 2024 | 1.332B |
| October 10, 2024 | 1.294B |
| October 09, 2024 | 1.254B |
| October 08, 2024 | 1.229B |
| October 07, 2024 | 1.132B |
| October 04, 2024 | 1.235B |
| October 03, 2024 | 1.195B |
| October 02, 2024 | 1.303B |
| October 01, 2024 | 1.276B |
| Date | Value |
|---|---|
| September 30, 2024 | 1.267B |
| September 27, 2024 | 1.235B |
| September 26, 2024 | 1.312B |
| September 25, 2024 | 1.219B |
| September 24, 2024 | 1.222B |
| September 23, 2024 | 1.245B |
| September 20, 2024 | 1.224B |
| September 19, 2024 | 1.219B |
| September 18, 2024 | 1.147B |
| September 17, 2024 | 1.124B |
| September 16, 2024 | 1.133B |
| September 13, 2024 | 1.173B |
| September 12, 2024 | 1.059B |
| September 11, 2024 | 1.054B |
| September 10, 2024 | 1.062B |
| September 09, 2024 | 1.101B |
| September 06, 2024 | 1.108B |
| September 05, 2024 | 1.104B |
| September 04, 2024 | 1.101B |
| September 03, 2024 | 1.079B |
| August 30, 2024 | 1.163B |
| August 29, 2024 | 1.142B |
| August 28, 2024 | 1.124B |
| August 27, 2024 | 1.102B |
| August 26, 2024 | 1.173B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
103.76M
Minimum
Oct 27 2023
2.828B
Maximum
Jun 13 2023
890.77M
Average
692.72M
Median
Enterprise Value Benchmarks
| Amicus Therapeutics Inc | 3.492B |
| Zoetis Inc | 84.35B |
| Annovis Bio Inc | 109.96M |
| NovaBay Pharmaceuticals Inc | 3.645M |
| Palatin Technologies Inc | 13.74M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.99M |
| Total Expenses (Quarterly) | 65.74M |
| EPS Diluted (Quarterly) | -0.81 |
| Earnings Yield | -10.74% |